BioLineRX Ltd
Symbol: BLRX (NASDAQ)
3.80
▼ (-2.67%) -0.104
Company Description:
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Key Stats
- Today's Open: $3.9
- Today's High: $3.97
- Today's Low: $3.79
- Today's Volume: 24.82K
- Yesterday Close: $3.9
- Yesterday High: $4.1248
- Yesterday Low: $3.73
- Yesterday Volume: 24.13K
- Last Min Volume: 1
- Last Min High: $3.924
- Last Min Low: $3.796
- Last Min VWAP: $3.924
Company Profile
- Name: BioLineRX Ltd
- Website: https://www.biolinerx.com
- Listed Date: 2011-07-25
- Location: ,
- Market Status: Active
- CIK Number: 0001498403
- SIC Code:
- SIC description:
- Market Cap: $17.05M
- Round Lot: 100
- Outstanding Shares: 4.26M
- Asset Type: ADRC
RECENT FILINGS FOR BLRX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-29 | 6-K | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-14 | 6-K | View |
| 2025-07-25 | 424B5 | View |
| 2025-06-30 | 6-K | View |
| 2025-05-30 | 6-K | View |
| 2025-05-27 | 6-K | View |
| 2025-05-23 | 6-K | View |
| 2025-04-11 | 424B5 | View |
| 2025-03-31 | 6-K | View |
| 2025-03-31 | 20-F | View |
| 2025-01-21 | 6-K | View |
| 2025-01-17 | 6-K | View |
| 2025-01-10 | SCHEDULE 13G | View |
| 2025-01-07 | 6-K | View |
| 2025-01-07 | 424B5 | View |
| 2025-01-06 | 6-K | View |
| 2024-12-27 | S-8 | View |
| 2024-11-25 | 6-K | View |
| 2024-11-21 | 6-K | View |
Latest News on BLRX